HRP20110384T1 - Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja - Google Patents
Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja Download PDFInfo
- Publication number
- HRP20110384T1 HRP20110384T1 HR20110384T HRP20110384T HRP20110384T1 HR P20110384 T1 HRP20110384 T1 HR P20110384T1 HR 20110384 T HR20110384 T HR 20110384T HR P20110384 T HRP20110384 T HR P20110384T HR P20110384 T1 HRP20110384 T1 HR P20110384T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- benzo
- group
- dihydro
- lower alkyl
- Prior art date
Links
- 208000020925 Bipolar disease Diseases 0.000 title claims abstract 12
- -1 heterocycle sulfamide derivatives Chemical class 0.000 title claims abstract 8
- 206010026749 Mania Diseases 0.000 title claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- KXSAIQPPGSSNKX-ZETCQYMHSA-N (2s)-6-chloro-2-[(sulfamoylamino)methyl]-2,3-dihydro-1,4-benzodioxine Chemical compound ClC1=CC=C2O[C@@H](CNS(=O)(=O)N)COC2=C1 KXSAIQPPGSSNKX-ZETCQYMHSA-N 0.000 claims 4
- 208000028683 bipolar I disease Diseases 0.000 claims 3
- 208000025307 bipolar depression Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol za upotrebu kod liječenja manije, naznačen time daR1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; je odabran iz skupine koju sačinjavaju i pri čemu b je cijeli broj od 0 do 4; i pri čemu c je cijeli broj od 0 do 2; svaki R5 je nezavisno odabran iz skupine koja sadrži halogen, niži alkil i nitro; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada jeili tada a je 1. Patent sadrži još 15 patentnih zahtjeva.
Claims (16)
1. Spoj formule (I)
[image]
ili njegova farmaceutski prihvatljiva sol za upotrebu kod liječenja manije,
naznačen time da
R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil;
R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2;
[image]
je odabran iz skupine koju sačinjavaju
[image]
[image]
[image]
i
[image]
pri čemu b je cijeli broj od 0 do 4; i pri čemu c je cijeli broj od 0 do 2;
svaki R5 je nezavisno odabran iz skupine koja sadrži halogen, niži alkil i nitro;
pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika,
pod uvjetom da kada
[image]
je
[image]
ili
[image]
tada a je 1.
2. Spoj formule (I)
[image]
ili njegova farmaceutski prihvatljiva sol za upotrebu kod liječenja bipolarnog poremećaja naznačen time da
R1 i R2 su svaki nezavisno odabrani iz skupine koja sadrži vodik i niži alkil;
R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2;
[image]
je odabran iz skupine koju sačinjavaju
[image]
[image]
[image]
i
[image]
pri čemu b je cijeli broj od 0 do 4; i pri čemu c je cijeli broj od 0 do 2;
svaki R5 je nezavisno odabran iz skupine koja se sastoji od halogena, nižeg alkila i nitro;
pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika,
pod uvjetom da kada
[image]
je
[image]
ili
[image]
tada a je 1.
3. Spoj formule (I)
[image]
ili njegova farmaceutski prihvatljiva sol za upotrebu kod liječenja bipolarne depresije, naznačen time da
R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil;
R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2;
[image]
je odabran iz skupine koju sačinjavaju
[image]
[image]
[image]
i
[image]
pri čemu b je cijeli broj od 0 do 4; i pri čemu c je cijeli broj od 0 do 2;
svaki R5 je nezavisno odabran iz skupine koja sadrži halogen, niži alkil i nitro;
pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika,
pod uvjetom da kada
[image]
je
[image]
ili
[image]
tada a je 1.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1, 2 i 3, naznačen time da
R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil;
R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil;
a je cijeli broj od 1 do 2;
[image]
je odabran iz skupine koju sačinjavaju
[image]
[image]
[image]
i
[image]
pri čemu b je cijeli broj od 0 do 2; i pri čemu c je cijeli broj od 0 do 1;
svaki R5 je nezavisno odabran iz skupine koja sadrži halogen, niži alkil i nitro;
pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika,
pod uvjetom da kada
[image]
je
[image]
ili
[image]
tada a je 1.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 4, naznačen time da
R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil;
R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil;
a je cijeli broj od 1 do 2;
[image]
je odabran iz skupine koju sačinjavaju
[image]
[image]
i
[image]
pri čemu b je cijeli broj od 0 do 2; i pri čemu c je 0;
svaki R5 je nezavisno odabran iz skupine koja sadrži halogen, niži alkil i nitro;
pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika,
pod uvjetom da kada
[image]
je
[image]
tada a je 1.
6. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 5, naznačen time da
R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil;
R4 je odabran iz skupine koju sačinjavaju vodik i metil;
a je cijeli broj od 1 do 2;
[image]
je odabran iz skupine koju sačinjavaju 2-(2,3-dihidro-benzo[1,4]dioksinil), 2-(benzo[1,3]dioksolil), 2-(3,4-dihidro-2H-benzo[1,4]dioksepinil), 2-(2,3-dihidro-benzo[1,4]dioksinil), 2-(6-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-fluoro-2,3-dihidro-benzo[1,4]dioksinil), 2-(kromanil), 2-(5-fluoro-2,3-dihidro-benzo[1,4]dioksinil), 2-(7-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-kloro-benzo[1,3]dioksolil), 2-(7-nitro-2,3-dihidro-benzo[1,4]dioksinil), 2-(7-metil-2,3-dihidro-benzo[1,4]dioksinil), 2-(5-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-bromo-2,3-dihidro-benzo[1,4]dioksinil), 2-(6,7-dikloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(8-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(2,3-dihidro-nafto[2,3-b][1,4]dioksinil) i 2-(4-metil-benzo[1,3]dioksolil);
pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika,
pod uvjetom da kada
[image]
je 2-(3,4-dihidro-2H-benzo[1,4]dioksepinil), tada a je 1.
7. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 6, naznačen time da
R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i metil;
R4 je odabran iz skupine koju sačinjavaju vodik i metil;
a je cijeli broj od 1 do 2;
[image]
je odabran iz skupine koju sačinjavaju 2-(benzo[1,3]dioksolil), 2-(2,3-dihidro-benzo[1,4]dioksinil), 2-(2,3-dihidro-benzo[1,4]dioksinil), 2-(6-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(7-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(7-metil-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-bromo-2,3-dihidro-benzo[1,4]dioksinil) i 2-(6,7-dikloro-2,3-dihidro-benzo[1,4]dioksinil).
8. Spoj prema bilo kojem od zahtjeva 1, 2 i 3 naznačen time da je spoj formule (I) odabran iz skupine koju sačinjavaju (2S)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2-ilmetil)-sulfamid i njegove farmaceutski prihvatljive soli.
9. Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2-ilmetil)-sulfamid i njegove farmaceutski prihvatljive soli za upotrebu kod liječenja manije.
10. Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2-ilmetil)-sulfamid i njegove farmaceutski prihvatljive soli za upotrebu kod liječenja bipolarnog poremećaja.
11. Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za upotrebu kod liječenja bipolarne depresije.
12. Spoj formule (II)
[image]
ili njegova farmaceutski prihvatljiva sol naznačen time da je za upotrebu kod liječenja manije.
13. Spoj formule (II)
[image]
ili njegova farmaceutski prihvatljiva sol naznačen time da je za upotrebu kod liječenja bipolarnog poremećaja.
14. Spoj formule (II)
[image]
ili njegova farmaceutski prihvatljiva sol naznačen time da je za upotrebu kod liječenja bipolarne depresije.
15. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 2 i 10, naznačen time da liječenje bipolarnog poremećaja sadrži liječenje depresije i manije kod bipolarnog poremećaja.
16. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 2 i 10, naznačen time da liječenje bipolarnog poremećaja sadrži liječenje depresije, manije i izmjene faza kod bipolarnog poremećaja.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75149305P | 2005-12-19 | 2005-12-19 | |
US11/612,222 US8937096B2 (en) | 2005-12-19 | 2006-12-18 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
PCT/US2006/048448 WO2007075695A2 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110384T1 true HRP20110384T1 (hr) | 2011-06-30 |
Family
ID=38007127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110384T HRP20110384T1 (hr) | 2005-12-19 | 2011-05-24 | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja |
Country Status (25)
Country | Link |
---|---|
US (1) | US8937096B2 (hr) |
EP (1) | EP1968573B1 (hr) |
JP (1) | JP5190372B2 (hr) |
KR (1) | KR20080085878A (hr) |
CN (1) | CN101370495B (hr) |
AT (1) | ATE501718T1 (hr) |
AU (1) | AU2006331857B2 (hr) |
BR (1) | BRPI0620085A2 (hr) |
CA (1) | CA2634255C (hr) |
CR (1) | CR10166A (hr) |
CY (1) | CY1111519T1 (hr) |
DE (1) | DE602006020775D1 (hr) |
EA (1) | EA015514B1 (hr) |
HK (1) | HK1124546A1 (hr) |
HR (1) | HRP20110384T1 (hr) |
IL (1) | IL192181A0 (hr) |
MY (1) | MY147643A (hr) |
NO (1) | NO20083032L (hr) |
NZ (1) | NZ569104A (hr) |
PL (1) | PL1968573T3 (hr) |
PT (1) | PT1968573E (hr) |
RS (1) | RS51790B (hr) |
SI (1) | SI1968573T1 (hr) |
SV (1) | SV2008002958A (hr) |
WO (1) | WO2007075695A2 (hr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
CN101754947A (zh) * | 2005-05-20 | 2010-06-23 | 詹森药业有限公司 | 磺酰胺衍生物的制备方法 |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
EA200870556A1 (ru) * | 2006-05-19 | 2009-06-30 | Янссен Фармацевтика Н.В. | Комбинированная терапия в лечении эпилепсии и родственных расстройств |
CA2688125A1 (en) | 2007-05-02 | 2008-11-13 | The Mclean Hospital Corporation | Methods and compositions for mitochondrial replacement therapy |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
MX2010011724A (es) * | 2008-04-29 | 2010-11-30 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
WO2009133109A1 (en) * | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
MX2010011498A (es) * | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
WO2010008776A2 (en) | 2008-06-23 | 2010-01-21 | Janssen Pharmaceutica Nv | Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems |
US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
WO2013049021A1 (en) | 2011-09-29 | 2013-04-04 | Janssen Pharmaceutica Nv | Process for the preparation of sulfamide derivatives |
WO2013045681A1 (en) | 2011-09-29 | 2013-04-04 | Janssen Pharmaceutica Nv | Improved process for the preparation of sulfamide derivatives |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2527861A (en) | 1948-05-07 | 1950-10-31 | Monsanto Chemicals | Mono alkyl sulfamides |
BE636655A (hr) | 1962-09-14 | |||
DE1211166B (de) | 1962-11-20 | 1966-02-24 | Ciba Geigy | Verfahren zur Herstellung neuer Sulfamide |
US3320314A (en) | 1964-01-22 | 1967-05-16 | Sandoz Ag | Chlorobenzyl sulfamides |
US3318952A (en) | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
US3383414A (en) | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
DE1542785A1 (de) | 1965-07-24 | 1970-05-06 | Bayer Ag | Insekten- und milbenabweisende Mittel |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US3621096A (en) | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
DE2022370A1 (de) | 1970-05-08 | 1971-12-02 | Bayer Ag | N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung |
US5212326A (en) | 1979-08-20 | 1993-05-18 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
FR2479825A1 (fr) | 1980-04-04 | 1981-10-09 | Fabre Sa Pierre | Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
GB8908085D0 (en) | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
US5238945A (en) | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
US5273993A (en) | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
US5194446A (en) | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
US5192785A (en) | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5189179A (en) | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
AU651244B2 (en) | 1991-09-19 | 1994-07-14 | Mcneilab, Inc. | Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol |
US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5258402A (en) | 1992-06-11 | 1993-11-02 | Mcneil-Ppc, Inc. | Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
DE69434652T2 (de) | 1993-12-23 | 2007-03-01 | Ortho-Mcneil Pharmaceutical, Inc. | Antikonvulsive pseudofructopyranose sulfamate |
GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
ATE204852T1 (de) | 1995-02-15 | 2001-09-15 | Bearsden Bio Inc | Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor |
JP3235448B2 (ja) | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | 1,4−ベンゾジオキサン誘導体の製法 |
US5998380A (en) | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
AU7655796A (en) | 1995-11-30 | 1997-06-19 | C & C Research Laboratories | Sulfamide derivatives |
AU1328197A (en) | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
JP2000507544A (ja) | 1996-03-25 | 2000-06-20 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
AU3501697A (en) | 1996-06-28 | 1998-01-21 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
DK0915697T3 (da) | 1996-06-28 | 2003-01-27 | Ortho Mcneil Pharm Inc | Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme |
CN1205193C (zh) | 1996-08-14 | 2005-06-08 | G·D·瑟尔公司 | 4-[5-甲基-3-苯基异噁唑-4-基]苯磺酰胺的晶型 |
ATE293458T1 (de) | 1996-08-23 | 2005-05-15 | Algos Pharm Corp | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen |
IL129276A (en) | 1996-10-08 | 2003-04-10 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in treating neuropathic pain |
US20020015713A1 (en) | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
US5935933A (en) | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
US5760007A (en) | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
DE69827149T2 (de) | 1997-08-15 | 2006-03-09 | Fairbanks, Carolyn Ann, Rochester | Agmatin für die behandlung neuropathischer schmerzen |
GB9803536D0 (en) | 1998-02-19 | 1998-04-15 | Black James Foundation | Histamine H,receptor ligands |
UA65607C2 (uk) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Фармацевтична композиція (варіанти) та спосіб її приготування |
DK72798A (da) | 1998-05-28 | 1998-05-28 | Novo Nordisk As | Treatment of GABA-uptake related disorders |
CN1302207A (zh) | 1998-05-29 | 2001-07-04 | 伊莱利利公司 | 双相性精神障碍的联合治疗 |
EP1100504A2 (en) | 1998-07-02 | 2001-05-23 | Eisai Co., Ltd. | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
US6541520B1 (en) | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
HUP0105154A3 (en) | 1999-01-19 | 2004-10-28 | Ortho Mcneil Pharm Inc | Use of anticonvulsant derivatives for treating cluster headaches |
AU3582600A (en) | 1999-01-21 | 2000-08-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating transformed migraine |
GB9903784D0 (en) | 1999-02-18 | 1999-04-14 | Lilly Co Eli | Pharmaceutical compounds |
CZ20013061A3 (cs) | 1999-02-24 | 2002-06-12 | University Of Cincinnati | Pouľití sulfamátových derivátů pro léčbu poruch kontroly impulsů |
EP1124416A1 (en) | 1999-03-15 | 2001-08-22 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
CA2369230A1 (en) | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
JP2003521471A (ja) | 1999-04-08 | 2003-07-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体 |
CA2369093C (en) | 1999-04-08 | 2005-10-18 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
ATE275950T1 (de) | 1999-05-04 | 2004-10-15 | Keith R Edwards | Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen |
ES2542868T3 (es) | 1999-06-14 | 2015-08-12 | Vivus, Inc. | Terapia de combinación para el tratamiento de diabetes asociada con la obesidad |
JP4977297B2 (ja) | 1999-08-20 | 2012-07-18 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | トラマドール物質及び抗痙攣薬を含んで成る組成物 |
FR2803848B1 (fr) | 2000-01-19 | 2002-02-15 | Adir | Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6322503B1 (en) | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
RU2268720C2 (ru) | 2000-07-07 | 2006-01-27 | Орто-Макнейл Фармасьютикал, Инк. | Противосудорожные производные, используемые для профилактики развития сахарного диабета и синдрома х |
DE10035227A1 (de) | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
JP2004505043A (ja) | 2000-08-02 | 2004-02-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | うつ病の治療で用いるに有用な抗痙攣性誘導体 |
PE20021046A1 (es) | 2000-09-30 | 2002-12-14 | Gruenenthal Chemie | Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina |
US7256184B2 (en) | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
AU2002240235B2 (en) | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
US6849635B2 (en) | 2001-05-07 | 2005-02-01 | Smithkline Beecham Corporation | Sulfonamides |
CA2448160A1 (en) | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
US20030100594A1 (en) | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
RU2226357C1 (ru) | 2003-02-12 | 2004-04-10 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева | Способ диагностики эпилепсии у пациентов с доклинической стадией болезни |
RU2246727C2 (ru) | 2003-02-12 | 2005-02-20 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) | Способ диагностики доклинической стадии эпилепсии |
AU2004231070B2 (en) | 2003-04-10 | 2008-02-14 | Amgen, Inc. | Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
DE60326773D1 (de) | 2003-04-16 | 2009-04-30 | Smithkline Beecham Corp | Peptid-deformylase-hemmer |
WO2004093912A1 (ja) | 2003-04-23 | 2004-11-04 | Kyowa Hakko Kogyo Co. Ltd. | 好中球性炎症疾患の予防および/または治療剤 |
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
US6949518B1 (en) | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
CN1845914A (zh) | 2003-09-02 | 2006-10-11 | 默克公司 | 用于治疗眼压过高的眼用组合物 |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
TW200612905A (en) * | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
CA2571881A1 (en) | 2004-06-22 | 2006-01-26 | Andreas P. Termin | Heterocyclic derivatives for modulation of calcium channels |
NZ552865A (en) | 2004-07-28 | 2009-09-25 | Janssen Pharmaceutica Nv | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US20060276528A1 (en) | 2004-08-24 | 2006-12-07 | Abdel-Magid Ahmed F | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
US20060047001A1 (en) | 2004-08-24 | 2006-03-02 | Parker Michael H | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
US20060241172A1 (en) | 2005-04-22 | 2006-10-26 | Wyeth | Benzodioxane and benzodioxolane derivatives and uses thereof |
CN101754947A (zh) | 2005-05-20 | 2010-06-23 | 詹森药业有限公司 | 磺酰胺衍生物的制备方法 |
US20070155824A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
US20070155823A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US20070155827A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US20070191452A1 (en) | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain |
US20070191474A1 (en) | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
TW200738669A (en) | 2006-02-22 | 2007-10-16 | Janssen Pharmaceutica Nv | Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide |
WO2007137164A2 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy and related disorders |
EA200870556A1 (ru) | 2006-05-19 | 2009-06-30 | Янссен Фармацевтика Н.В. | Комбинированная терапия в лечении эпилепсии и родственных расстройств |
US20090182141A1 (en) | 2008-01-07 | 2009-07-16 | Ahmed Abdel-Magid | Process for the preparation of sulfamide derivatives |
US20090247617A1 (en) | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
EP2280951A2 (en) | 2008-03-26 | 2011-02-09 | Janssen Pharmaceutica, N.V. | Processes for the preparation of benzo-fused dioxin derivatives |
US20090247618A1 (en) | 2008-03-26 | 2009-10-01 | Ballentine Scott A | Process for preparation of benzo-fused heteroaryl derivatives |
BRPI0822454A2 (pt) | 2008-03-26 | 2015-06-16 | Janssen Pharmaceutica Nv | Processo para preparação de sulfamatos de heteroarila benzo-fundidos e forma cristalina de n-(((2s)-6-cloro-2,3-diidro-1,4-benzodioxin-2yl)metil-su lfamida |
WO2010008776A2 (en) | 2008-06-23 | 2010-01-21 | Janssen Pharmaceutica Nv | Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
-
2006
- 2006-12-18 US US11/612,222 patent/US8937096B2/en not_active Expired - Fee Related
- 2006-12-19 AU AU2006331857A patent/AU2006331857B2/en not_active Ceased
- 2006-12-19 PT PT06847788T patent/PT1968573E/pt unknown
- 2006-12-19 NZ NZ569104A patent/NZ569104A/en not_active IP Right Cessation
- 2006-12-19 EP EP06847788A patent/EP1968573B1/en active Active
- 2006-12-19 CA CA2634255A patent/CA2634255C/en not_active Expired - Fee Related
- 2006-12-19 JP JP2008547444A patent/JP5190372B2/ja not_active Expired - Fee Related
- 2006-12-19 WO PCT/US2006/048448 patent/WO2007075695A2/en active Application Filing
- 2006-12-19 DE DE602006020775T patent/DE602006020775D1/de active Active
- 2006-12-19 AT AT06847788T patent/ATE501718T1/de active
- 2006-12-19 SI SI200631014T patent/SI1968573T1/sl unknown
- 2006-12-19 RS RS20110225A patent/RS51790B/en unknown
- 2006-12-19 CN CN2006800527846A patent/CN101370495B/zh not_active Expired - Fee Related
- 2006-12-19 KR KR1020087017559A patent/KR20080085878A/ko active IP Right Grant
- 2006-12-19 PL PL06847788T patent/PL1968573T3/pl unknown
- 2006-12-19 BR BRPI0620085-0A patent/BRPI0620085A2/pt not_active IP Right Cessation
- 2006-12-19 EA EA200870086A patent/EA015514B1/ru not_active IP Right Cessation
-
2008
- 2008-06-15 IL IL192181A patent/IL192181A0/en unknown
- 2008-06-18 MY MYPI20082187A patent/MY147643A/en unknown
- 2008-06-19 SV SV2008002958A patent/SV2008002958A/es unknown
- 2008-07-04 NO NO20083032A patent/NO20083032L/no not_active Application Discontinuation
- 2008-07-21 CR CR10166A patent/CR10166A/es not_active Application Discontinuation
-
2009
- 2009-03-17 HK HK09102535.9A patent/HK1124546A1/xx not_active IP Right Cessation
-
2011
- 2011-05-23 CY CY20111100506T patent/CY1111519T1/el unknown
- 2011-05-24 HR HR20110384T patent/HRP20110384T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0620085A2 (pt) | 2011-11-01 |
AU2006331857A1 (en) | 2007-07-05 |
JP2009520030A (ja) | 2009-05-21 |
EP1968573A2 (en) | 2008-09-17 |
CR10166A (es) | 2008-11-24 |
JP5190372B2 (ja) | 2013-04-24 |
EA015514B1 (ru) | 2011-08-30 |
CN101370495B (zh) | 2011-10-19 |
WO2007075695A3 (en) | 2007-11-15 |
US20070155826A1 (en) | 2007-07-05 |
DE602006020775D1 (de) | 2011-04-28 |
CA2634255A1 (en) | 2007-07-05 |
EP1968573B1 (en) | 2011-03-16 |
EA200870086A1 (ru) | 2008-12-30 |
PL1968573T3 (pl) | 2011-07-29 |
IL192181A0 (en) | 2009-08-03 |
US8937096B2 (en) | 2015-01-20 |
SV2008002958A (es) | 2010-01-18 |
SI1968573T1 (sl) | 2011-06-30 |
MY147643A (en) | 2012-12-31 |
WO2007075695A2 (en) | 2007-07-05 |
KR20080085878A (ko) | 2008-09-24 |
HK1124546A1 (en) | 2009-07-17 |
RS51790B (en) | 2011-12-31 |
NO20083032L (no) | 2008-09-16 |
CA2634255C (en) | 2014-08-05 |
PT1968573E (pt) | 2011-04-29 |
CY1111519T1 (el) | 2015-08-05 |
ATE501718T1 (de) | 2011-04-15 |
CN101370495A (zh) | 2009-02-18 |
NZ569104A (en) | 2011-04-29 |
AU2006331857B2 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110384T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja | |
HRP20100007T1 (hr) | Upotreba benzo-spojenih heterocikličkih derivata sulfamida za liječenje boli | |
HRP20110726T2 (hr) | Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti | |
HRP20120018T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida kao neurozaštitnih sredstava | |
HRP20110008T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za smanjenje razine masnoća i šećera u krvi | |
CA2570606A1 (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
JP2009520030A5 (hr) | ||
JP2009520036A5 (hr) | ||
JP2009520032A5 (hr) | ||
JP2009520031A5 (hr) | ||
JP2009520033A5 (hr) | ||
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
BR0116624A (pt) | Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação | |
AR106689A2 (es) | Dentífrico antiplaca y desensibilizante | |
TW200716595A (en) | Chromane and chromene derivatives and uses thereof | |
BR0309106A (pt) | Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm | |
AR065822A1 (es) | Derivados de tiazolidina. composiciones farmaceuticas y usos como antagonistas del receptor orexina | |
HUP0400250A2 (hu) | 5-HT6 és/vagy 5-HT7 szerotonin receptorok ligandumaként alkalmazott 5-halogén-triptamin-származékok, előállításuk és alkalmazásuk gyógyszerkészítmények előállítására | |
AR050530A1 (es) | Derivados de heteroaril sulfamida benzo-fusionada utiles como agentes anticonvulsivos | |
BRPI0814529B8 (pt) | derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas de alfa2c para uso no tratamento de doenças do sistema nervoso periférico e central | |
FR2804023B1 (fr) | Complement nutritionnel a base d'huile de pepins de cassis | |
RS53507B1 (en) | PHARMACEUTICAL COMPOSITION AGAINST MALARIA | |
ES2180041T3 (es) | Derivados de 5-oxido de piridazino(4,5-b)quinoleina, su preparacion y su uso como antagonistas de glicina. | |
UY29892A1 (es) | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones |